![](/img/cover-not-exists.png)
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
Massard, Christophe, Soria, Jean-Charles, Anthoney, D. Alan, Proctor, A., Scaburri, Angela, Pacciarini, Maria Adele, Laffranchi, Bernard, Pellizzoni, Cinzia, Kroemer, Guido, Armand, Jean-Pierre, BalheVolume:
10
Journal:
Cell Cycle
DOI:
10.4161/cc.10.6.15075
Date:
March, 2011
File:
PDF, 1.46 MB
2011